Anti-SARS-CoV-2 Spike (CT)
Code | Size | Price |
---|
LEI-S540-20ug | 20 ug | £199.00 |
Quantity:
LEI-S540-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Images
Further Information
Concentration:
1.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Spike antibody was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Spike glycoprotein. The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Spike protein.
Long Description:
A coronavirus, SARS-CoV-2 was first identified in 2019 (COVID-19). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS-CoV-2 can be mediated by the binding of the viral spike protein, a glycosylated protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
NCBI Gene:
43740568
Target:
SARS-CoV-2
References
1. Gorbalenya. bioRxiv: (2020).
2. Hui et al. Int J Infect Dis. (2020);91:264-266.
3. Belouzard et al. Viruses. (2012);4(6):1011-33.
4. Lee et al. J Virol. (2006);80(8):4079-87.
5. Wan et al. J Virol. (2020).
6. Wrapp et al. Science. (2020).
Related Products
Product Name | Product Code | Supplier | Anti-SARS-CoV Spike (16aa - Intermediate Domain) | LEI-S541 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-SARS-CoV Spike (17aa - Intermediate Domain) | LEI-S542 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-SARS-CoV Spike (15aa - Intermediate Domain) | LEI-S543 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-SARS-CoV Spike (NT) | LEI-S544 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Severe Acute Respiratory Syndrome Spike (CT) Blocking Peptide | LEI-S549 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Severe Acute Respiratory Syndrome Spike (Intermediate Domain - 1) | LEI-S550 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Severe Acute Respiratory Syndrome Spike (Intermediate Domain - 2) | LEI-S551 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Severe Acute Respiratory Syndrome Spike (Intermediate Domain - 3) | LEI-S552 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Severe Acute Respiratory Syndrome Spike (NT) Blocking Peptide | LEI-S553 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||